Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus

Epilepsy and Behavior

Volumn 64, Issue , 2016, Pages 110-115

  Brigo, Francesco ^a,b   Bragazzi, Nicola ^c   Nardone, Raffaele ^b,d   Trinka, Eugen ^d,e,f  

^a UNIVERSITY OF VERONA   (Italy)

^b FRANZ TAPPEINER HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF SALZBURG   (Austria)

^f UNIVERSITY FOR HEALTH SCIENCES   (Austria)

Author keywords

Clinical trials randomized controlled; Levetiracetam; Meta analysis; Phenytoin; Status epilepticus; Valproate

Indexed keywords

LEVETIRACETAM; PHENYTOIN; VALPROIC ACID; ANTICONVULSIVE AGENT; ETIRACETAM; PIRACETAM;

CLINICAL EFFECTIVENESS; CONVULSION; DRUG SAFETY; EPILEPTIC STATE; EVIDENCE BASED MEDICINE; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY HEALTH CARE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; STATUS EPILEPTICUS;

ANTICONVULSANTS; HUMANS; PHENYTOIN; PIRACETAM; STATUS EPILEPTICUS; VALPROIC ACID;

EID: 84991491224     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2016.09.030     Document Type: Review

References (30)

1. [1] Trinka, E., Cock, H., Hesdorffer, D., et al. A definition and classification of status epilepticus — report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 56 (2015), 1515–1523.
2. [2] DeLorenzo, R.J., Pellock, J.M., Towne, A.R., Boggs, J.G., Epidemiology of status epilepticus. J Clin Neurophysiol 12 (1995), 316–325.
3. [3] Trinka, E., Höfler, J., Leitinger, M., Brigo, F., Pharmacotherapy for status epilepticus. Drugs 75 (2015), 1499–1521.
4. [4] Trinka, E., Dobesberger, J., New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord 2 (2009), 79–91.
5. [5] Yasiry, Z., Shorvon, S.D., The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure 23 (2014), 167–174.
6. [6] Mundlamuri, R.C., Sinha, S., Subbakrishna, D.K., et al. Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam—pilot study. Epilepsy Res 114 (2015), 52–58.
7. [7] Chakravarthi, S., Goyal, M.K., Modi, M., Bhalla, A., Singh, P., Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci 22 (2015), 959–963.
8. [8] Misra, U.K., Kalita, J., Patel, R., Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 67 (2006), 340–342.
9. [9] Agarwal, P., Kumar, N., Chandra, R., Gupta, G., Antony, A.R., Garg, N., Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 16 (2007), 527–532.
10. [10] Mehta, V., Singhi, P., Singhi, S., Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol 22 (2007), 1191–1197.
11. [11] Gilad, R., Izkovitz, N., Dabby, R., et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 118 (2008), 296–300.
12. [12] Chen, L., Feng, P., Wang, J., et al. Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. J Clin Neurosci 16 (2009), 524–526.
13. [13] Malamiri, R.A., Ghaempanah, M., Khosroshahi, N., Nikkhah, A., Bavarian, B., Ashrafi, M.R., Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol 16 (2012), 536–541.
14. [14] Brigo, F., Storti, M., Del Felice, A., Fiaschi, A., Bongiovanni, L.G., IV valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol 19 (2012), 1180–1191.
15. [15] Trinka, E., Höfler, J., Zerbs, A., Brigo, F., Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs 28 (2014), 623–639.
16. [16] Lowenstein, D.H., Bleck, T., Macdonald, R.L., It's time to revise the definition of status epilepticus. Epilepsia 40 (1999), 120–122.
17. [17] Higgins, J.P.T., Green, S., (eds.) Handbook for systematic reviews of interventions version 5.1.0 (updated March 2011) The Cochrane collaboration, 2011.
18. [18] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
19. [19] Glenny, A.M., Altman, D.G., Song, F., et al. International Stroke Trial Collaborative Group. Health Technol Assess 9 (2005), 1–134 [iii–iv].
20. [20] ICWG, Report of the indirect comparisons working group to the pharmaceutical benefits advisory committee: assessing indirect comparisons. 2009, Australian Government Department of Health and Aging, Canberra [Available from: http://www.pbs.gov.au/industry/useful-resources/PBAC_feedback_files/ICWG%20Report%20FINAL2.pdf (accessed 27th October 2015)].
21. [21] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
22. [22] Bucher, H.C., Guyatt, G.H., Griffith, L.E., Walter, S.D., The results of direct and indirect treatment comparisons in meta-analysis or randomized controlled trials. J Clin Epidemiol 50 (1997), 683–691.
23. [23] Otoul, C., Arrigo, C., van Rijckevorsel, K., French, J.A., Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28 (2005), 72–78.
24. [24] Brigo, F., Igwe, S.C., Nardone, R., Tezzon, F., Bongiovanni, L.G., Trinka, E., A common reference-based indirect comparison meta-analysis of intravenous valproate versus intravenous phenobarbitone for convulsive status epilepticus. Epileptic Disord 15 (2013), 314–323.
25. [25] Zaccara, G., Giovannelli, F., Maratea, D., Fadda, V., Verrotti, A., Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure 22 (2013), 528–536.
26. [26] Brigo, F., Nardone, R., Tezzon, F., Trinka, E., A common reference-based indirect comparison meta-analysis of buccal versus intranasal midazolam for early status epilepticus. CNS Drugs 29 (2015), 741–757.
27. [27] Cohn, L.D., Becker, B.J., How meta-analysis increases statistical power. Psychol Methods 8 (2003), 243–253.
28. [28] Prasad, M., Krishnan, P.R., Sequeira, R., Al-Roomi, K., Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev, 9, Sep 2014 10, CD003723, 10.1002/14651858.CD003723.pub3.
29. [29] Cock, H.R., ESETT Group, Established status epilepticus treatment trial (ESETT). Epilepsia 52:Suppl. 8 (2011), 50–52.
30. [30] Bleck, T., Cock, H., Chamberlain, J., et al. The established status epilepticus trial 2013. Epilepsia 54:Suppl. 6 (2013), 89–92.